FGEN: FibroGen Inc Company Profile & Statistics

About

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Info & Links

CEO

Thane Wettig

Headquarters

409 ILLINOIS STREET
SAN FRANCISCO, CA 94158, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

105

Employees

486

FibroGen Inc Statistics

Valuation Measures

Market Capitalization²

34.96M

Enterprise Value

-23.27M

Enterprise Value/EBITDA(ttm)

0.21

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.19

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

78.09%

Operating Margin(ttm)

-67.66%

Profit Margin(ttm)

-83.42%

Return on Equity(ttm)

Return on Invested Capital(ttm)

97.15%

Return on Assets(ttm)

-36.17%

Income Statement

Revenue(ttm)

180.01M

Revenue Per Share(ttm)

1.79

Gross Profit(ttm)

138.38M

EBITDA(ttm)³

-111.83M

Net Income Available to Common(ttm)

-121.79M

Diluted EPS(ttm)

-1.23

Share Statistics

Beta (5Y Monthly)

0.82

52-Week Change

-46.84%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

100.77M

Dividend Yield

0.00%

Float⁴

98.78M

% Held by Insiders

1.98%

% Held by Institutions

72.71%

Balance Sheet

Total Cash(mrq)

131.00M

Total Cash Per Share(mrq)

1.30

Total Debt(mrq)

72.78M

Total Debt/Equity(mrq)

-32.61%

Current Ratio(mrq)

1.28%

Quick Ratio(mrq)

1.16%

Book Value Per Share(mrq)

-2.21

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.07

Free Cash Flow(ytd)

-106.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FGEN

FibroGen Inc

FibroGen Inc Profile